Literature DB >> 17212719

Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study.

S Ota1, M Mclimont, M D Carcao, V S Blanchette, N Graham, E Paradis, B M Feldman.   

Abstract

The creation of acceptable standard definitions for terms used in the care and assessment of haemophilia patients has become increasingly important, as a growing number of international clinical studies have been initiated. The Delphi approach has been used in health research to reach consensus in large groups and can be used to develop definitions by using several iterations of surveys eliciting opinions from specialists in the field. Three consecutive surveys were designed based on the Delphi approach and distributed to specialist physicians, nurses and physiotherapists in order to develop definitions for seven haemophilia terms: 'primary prophylaxis', 'secondary prophylaxis', 'target joint', 'joint bleed', 'significant soft-tissue bleed', 'superficial soft-tissue bleed' and 'mucosal bleed'. Suggestions were solicited, compiled into a subsequent survey and fed back to the group to rank-order the importance of each suggested component of the definition. Final definitions were created using the top-ranked suggestions and sent back to the experts for approval. Five of the seven terms were highly endorsed with greater than 90% agreement. Some differences in agreement were found when analysed by profession. Haemophilia terms were successfully defined using the Delphi approach. Further refinement from members of the international haemophilia community will ensure that comprehensive standard definitions can be used in multicentre studies in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17212719     DOI: 10.1111/j.1365-2516.2006.01409.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

1.  Joint Health Status of Hemophilia Patients in Jodhpur Region.

Authors:  Vikas Payal; Pramod Sharma; N P Chhangani; Yojana Janu; Yudhavir Singh; Akash Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-11-02       Impact factor: 0.900

2.  A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A.

Authors:  Chiai Nagae; Atsuki Yamashita; Tomoko Ashikaga; Mika Mori; Mieko Akita; Kaoru Kitsukawa; Satoshi Yamazaki; Kimie Yoshikawa; Hitoshi Yamamoto; Masashi Taki
Journal:  Int J Hematol       Date:  2016-04-28       Impact factor: 2.490

3.  Effect of Prophylactic Management of Hemophilia on Bleeding Episodes.

Authors:  Suman Roy; Arun Kumar De
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-03       Impact factor: 0.900

4.  Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada.

Authors:  J St-Louis; D J Urajnik; F Ménard; S Cloutier; R J Klaassen; B Ritchie; G E Rivard; M Warner; V Blanchette; N L Young
Journal:  BMC Hematol       Date:  2016-05-05

5.  Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.

Authors:  Meriem Bensadok; Abdulkareem Almomen; Azzam Alzoebie; Soraya Benchikh El Fegoun; Yasser Wali; Fati Hamzy; Nemra Gaid Mehalhal; Fatiha Grifi; Selma Hamdi; Naima Mesli; Tarek Owaidah; Hossam Ali Saad; Nouredine Sidi Mansour; Hadj Touhami
Journal:  Blood Coagul Fibrinolysis       Date:  2017-03       Impact factor: 1.276

6.  Muscle strengthening intervention for boys with haemophilia: Developing and evaluating a best-practice exercise programme with boys, families and health-care professionals.

Authors:  Ferhana Hashem; David Stephensen; Wendy I Drechsler; Melanie Bladen; Liz Carroll; Pellatt-Higgins Tracy; Eirini-Christina Saloniki
Journal:  Health Expect       Date:  2020-08-17       Impact factor: 3.377

Review 7.  Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B.

Authors:  Johnny N Mahlangu
Journal:  Ther Adv Hematol       Date:  2018-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.